Epigenetic differences in NCOA2: a novel biomarker that predicts prognosis in clear cell renal cell carcinoma

Objectives: Kidney cancer is one of the top ten cancers worldwide, and clear cell renal cell carcinoma (ccRCC) is the most common pathohistological type of kidney cancer. This study aimed to decipher the diagnostic and prognostic value of NCOA2 for ccRCC survival based on its expression and methylation. Methods: We explored the mRNA and protein expression, DNA methylation, prognosis, cell function, and relevant immune infiltration of NCOA2 in ccRCC using data from public databases. Furthermore, GSEA (Gene Set Enrichment Analysis) was used to dissect the cell functions and signal pathways associated with NCOA2 involved in ccRCC and evaluated the close correlation between NCOA2 expression and immune cells. Finally, RT-qPCR (quantitative reverse transcription PCR) and IHC (immunohistochemistry) were utilized to verify the expression of NCOA2 in ccRCC among the tumor and ad-jacent normal tissues collected from patients. Results: NCOA2 was lowly expressed in ccRCC tissue, which resulted from its methylation. High NCOA2 expression and low beta value of one of the CpG sites predicted better prognosis in patients with ccRCC. GSEA results and analysis of immune infiltration revealed that NCOA2 was associated with PD-1/PD-L1 expression and infiltration of other immune cells in ccRCC. Conclusions: NCOA2 has great potential to serve as a novel biomarker that can predict prognosis in ccRCC and may become a new therapeutic target in patients with late-stage ccRCC.

Automated summary

This study aimed to investigate the diagnostic and prognostic value of NCOA2 in clear cell renal cell carcinoma (ccRCC) based on its expression and methylation. The results showed that NCOA2 was lowly expressed in ccRCC tissue and was associated with PD-1/PD-L1 expression and infiltration of other immune cells. The findings suggest that NCOA2 has the potential to serve as a novel biomarker for predicting prognosis and a therapeutic target in late-stage ccRCC patients.